A multicenter study of the clinicopathological characteristics and a risk prediction model of early-stage breast cancer with hormone receptor-positive/human epidermal growth factor receptor 2-low expression

作     者：Ling Xin Qian Wu Chongming Zhan Hongyan Qin Hongyu Xiang Min Gao Xuening Duan Yinhua Liu Jingming Ye Chinese Society of Breast Surgery(CSBrS) Chinese Society of Surgery of Chinese Medical Association Ling Xin;Qian Wu;Chongming Zhan;Hongyan Qin;Hongyu Xiang;Min Gao;Xuening Duan;Yinhua Liu;Jingming Ye;Chinese Society of Breast Surgery (CSBrS);Chinese Society of Surgery of Chinese Medical Association

作者机构：Department of Breast and ThyroidPeking University First HospitalBeijing 100034China Jun Yi Tai He Medical Technology Co.Ltd.Beijing 100024China 不详 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2023年第136卷第24期

页      面：2967-2973页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by grants from the Youth Cultivation Fund of Beijing Medical Ward Foundation(No.20180502) Beijing Medical Ward Foundation(Nos.YXJL-2016-0040-0065,YXJL-2020-0941-0736) Chinese junior breast surgeon research award fund(No.2020-CHPASLP-01) 

主　　题：Breast cancer Hormone positive HER2-low expression Multicenter study 

摘      要：Background:In light of the significant clinical benefits of antibody-drug conjugates in clinical trials,the human epidermal growth factor receptor 2(HER2)-low category in breast cancers has gained increasing ***,we studied the clinicopathological characteristics of Chinese patients with hormone receptor(HR)-positive/HER2-low early-stage breast cancer and developed a recurrence risk prediction ***:Female patients with HR-positive/HER2-low early-stage breast cancer treated in 29 hospitals of the Chinese Society of Breast Surgery(CSBrS)from Jan 2015 to Dec 2016 were *** clinicopathological data and prognostic information were collected,and machine learning methods were used to analyze the prognostic ***:In total,25,096 patients were diagnosed with breast cancer in 29 hospitals of CSBrS from Jan 2015 to Dec 2016,and clinicopathological data for 6486 patients with HER2-low early-stage breast cancer were *** them,5629 patients(86.79%)were *** median follow-up time was 57 months(4,76 months);the 5-year disease-free survival(DFS)rate was 92.7%,and the 5-year overall survival(OS)rate was 97.7%.In total,412 cases(7.31%)of metastasis were observed,and 124(2.20%)patients *** Cox regression analysis revealed that T stage,N stage,lymphovascular thrombosis,Ki-67 index,and prognostic stage were associated with recurrence and metastasis(P0.05).A recurrence risk prediction model was established using the random forest method and exhibited a sensitivity of 81.1%,specificity of 71.7%,positive predictive value of 74.1%,and negative predictive value of 79.2%.Conclusion:Most of patients with HER2-low early-stage breast cancer were HR-positive,and patients had favorable outcome;tumor N stage,lymphovascular thrombosis,Ki-67 index,and tumor prognostic stage were prognostic *** HR-positive/HER2-low early-stage breast cancer recurrence prediction model established based on the random forest method h